Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highly active antiretroviral therapy

Current Opinion in Oncology

Volumn 15, Issue 5, 2003, Pages 382-388

  Palefsky, Joel M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasia; Highly active antiretroviral therapy; Human immunodeficiency virus; Human papillomavirus

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER REGRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; WART VIRUS;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HIV INFECTIONS; HUMANS; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 0041330438     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200309000-00007     Document Type: Review

References (43)

1. Walboomers JM, Jacobs MV, Manos MM, et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
2. Munoz N, Bosch FX, de Sanjose S, et al.: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527. This paper represents the most comprehensive analysis of the oncogenic risk of the most common genital HPV types. Comparison of oncogenic risk with phylogenetic classification revealed good correlation.
3. Palefsky JM, Minkoff H, Kalish LA, et al.: Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999, 91:226-236.
4. Broker TR, Jin G, Croom-Rivers A, et al.: Viral latency: the papillomavirus model. Dev Biol 2001, 106:443-451. This was the first study to show that HIV-positive women likely have many more HPV types than commonly recognized using standard HPV detection techniques. While none of these newly described types have been shown to be oncogenic, their role in the pathogenesis of CIN is not known.
5. Terai M, Burk RD: Identification and characterization of 3 novel genital human papillomaviruses by overlapping polymerase chain reaction: candHPV89, candHPV90 and candHPV91. J Infect Dis 2002, 185:1794-1797.
6. de Villiers EM: Taxonomic classification of papillomaviruses. Papillomavirus Report 2001, 12:57-63.
7. Strickler H, Palefsky JM, Shah KV, et al.: The weak association of HPV 16 with immune status in HIV-seropositive women. J Natl Cancer Inst 2003 (in press) This paper shows that the relationship between HPV 16 prevalence is not as clearly related to lower CD4+ levels in HIV-positive women as other HPV types. This observation suggests that control of HPV 16 is not as closely tied to immune response as other HPV types and may help to explain why HPV 16 is the most common oncogenic HPV type in the general population of immunocompetent women.
8. Jamieson DJ, Duerr A, Burk R, et al.: Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection. Am J Obstet Gynecol 2002, 186:21-27.
9. Sun XW, Kuhn L, Ellerbrock TV, et al.: Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997, 337:1343-1349.
10. Ahdieh L, Munoz A, Vlahov D, et al.: Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. Am J Epidemiol 2000, 151:1148-1157.
11. Minkoff H, Feidman J, DeHovitz J, et al.: A longitudinal study of human papillomavirus carriage in human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women. Am J Obstet Gynecol 1998, 178:982-986.
12. Levi JE, Kieter B, Quint WG, et al.: High prevalence of human papillomavirus (HPV) infections and high frequency of multiple HPV genotypes in human immunodeficiency virus-infected women in Brazil. J Clin Microbiol 2002, 40:3341-3345.
13. Mayaud P, Gill DK, Weiss HA, et al.: The interrelation of HIV, cervical human papillomavirus, and neoplasia among antenatal clinic attenders in Tanzania. Sex Transm Infect 2001, 77:248-254.
14. Mandelblatt JS, Kanetsky P, Eggert L, et al.: Is HIV infection a cofactor for cervical squamous cell neoplasia? Cancer Epidemiol Biomarkers Prev 1999, 8:97-106.
15. Massad LS, Riester KA, Anastos KM, et al.: Prevalence and predictors of squamous cell abnormalities in Papanicolaou smears from women infected with HIV-1, Women's Interagency HIV Study Group. J Acq Immun Defic Syndr Hum Retrovirol 1999, 21:33-41.
16. Duerr A, Kieke B, Warren D, et al.: Human papillomavirus-associated cervical cytologic abnormalities among women with or at risk of infection with human immunodeficiency virus. Am J Obstet Gynecol 2001, 184:584-590.
17. Chirenje ZM, Loeb L, Mwale M, et al.: Association of cervical SIL and HIV-1 infection among Zimbabwean women in an HIV/STI prevention study. Int J STD AIDS 2002, 13:765-768.
18. Ellerbrock TV, Chiasson MA, Bush TJ, et al.: Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000, 283:1031-1037.
19. Heselmeyer K, Macville M, Schrock E, et al.: Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q. Genes Chromosomes Cancer 1997, 19:233-240.
20. Heselmeyer K, du Manoir S, Blegen H, et al.: A recurrent pattern of chromosomal aberrations and immunophenotypic appearance defines anal squamous cell carcinomas. Br J Cancer 1997, 76:1271-1278.
21. Heard I, Schmitz V, Costagliola D, et al.: Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS 1998, 12:1459-1464.
22. Lillo FB, Ferrari D, Veglia F, et al.: Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis 2001, 184:547-551.
23. Conley L, Ellerbrock TV, Bush TJ, et al.: HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002, 359:108-113.
24. Palefsky JM, Holly EA, Ralston ML, et al.: The effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection. J Acq Immunodefic Syndr 2001, 28:422-428. This is the first description of the effect of HAART on HPV-associated anogenital neoplasia, showing that HAART had no effect on regression of high-grade anal intraepithelial neoplasia.
25. Minkoff H, Ahdieh L, Massad LS, et al.: The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS 2001, 15:2157-2164. This is one of the largest prospective studies of the effect of HAART on the natural history of CIN in HIV-positive women; disease outcome was measured using cytology but not colposcopy and histology.
26. Heard I, Tassie JM, Kazatchkine MD, et al.: Highly active antiretrovirai therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS 2002, 16:1799-1802. This is the largest study to examine the effect of HAART on the natural history of CIN using the gold standard of colposcopically directed biopsy as the outcome measure.
27. Orlando G, Fasolo MM, Schiavini M, et al.: Role of highly active antiretroviral therapy in human papillomavirus-induced genital dysplasia in HIV-1-infected patients. AIDS 1999, 13:424-425.
28. Moore AL, Sabin CA, Madge S, et al.: Highly active antiretrovirai therapy and cervical intraepithelial neoplasia. AIDS 2002, 16:927-929.
29. Greenspan D, Canchola AJ, MacPhail LA, et al.: Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet 2001, 357:1411-1412.
30. King MD, Reznik DA, O'Daniels CM, et al.: Human papillomavirus-associated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: an emerging infection. Clin Infect Dis 2002, 34:641-648.
31. Centers for Disease Control and Prevention. Sexually transmitted infections treatment guidelines 2002. MMWR 2002, 51 (No. RR-6): 59
32. Kurman RJ, Henson DE, Herbst AL, et al.: Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA 1994, 271:1866-1869.
33. Tate DR, Anderson RJ: Recrudescence of cervical dysplasia among women who are infected with the human immunodeficiency virus: a case-control analysis. Am J Obstet Gynecol 2002, 186:880-882.
34. Maiman M: Management of cervical neoplasia in human immunodeficiency virus-infected women. J Natl Cancer Inst Monogr 1998, 68:43-49.
35. Robinson WR, Hamilton CA, Michaels SH, et al.: Effect of excisional therapy and highly active antiretroviral therapy on cervical intraepithelial neoplasia in women infected with human immunodeficiency virus. Am J Obstet Gynecol 2001, 184:538-543.
36. IARC: IARC Working group on the evaluation of carcinogenic risk to humans. Human immunodeficiency viruses and human T-cell lymphotropic viruses. IARC Monographs 1996, 66.
37. International Collaboration on HIV and Cancer 2000: Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000, 92:1823-1830.
38. Sitas F, Pacella-Norman R, Carrara H, et al.: The spectrum of HIV-1 related cancers in South Africa. Int J Cancer 2000, 88:489-492.
39. Gichangi P, De Vuyst H, Estambale B, et al.: HIV and cervical cancer in Kenya. Int J Gynaecol Obstet 2002, 76:55-63.
40. Frisch M, Biggar RJ, Goedert JJ: Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000, 92:1500-1510.
41. Franceschi S, Dal Maso L, Arniani S, et al.: Risk of cancer other than Kaposi's sarcoma and non-Hodgkin's lymphoma in persons with AIDS in Italy. Cancer and AIDS Registry Linkage Study. Br J Cancer 1998, 78:966-970.
42. Serraino D, Carrieri P, Pradier C, et al.: Risk of invasive cervical cancer among women with, or at risk for, HIV infection. Int J Cancer 1999, 82:334-337.
43. Serraino D, Dal Maso L, La Vecchia C, et al.: Invasive cervical cancer as an AIDS-defining illness in Europe. AIDS 2002, 16:781-786.